– USA, CA – SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, announced the appointment of Tyler Binney to its Board of Directors, bringing over two decades of commercial leadership experience that will be instrumental to mission to deliver a new treatment alternative to patients with autoimmune conditions, including rheumatoid arthritis.
About Tyler Binney
With over 20 years of proven leadership experience in the medical device industry, Tyler Binney most recently served as President and CEO of Relievant Medical Systems, which Boston Scientific acquired in November 2023 for an upfront payment of $850 million, plus performance-based earnouts. Previously, he served as President and GM of the Interventional Urology Business Unit at Teleflex and as VP of Sales at NeoTract, where he led the successful commercialization of the UroLift® System, contributing to its $1.1 billion acquisition by Teleflex.
About SetPoint Medical
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.
For more information: https://setpointmedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.